Novo Nordisk A/S (NYSE: NVO) Investor Alert: Lawsuit alleges False and Misleading Statements

An investor, who purchased shares of Novo Nordisk A/S (NYSE: NVO), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Novo Nordisk A/S in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and for certain investors are short and strict deadlines running. Deadline: September 30, 2025. NYSE: NVO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Denmark based Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025. The Company attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."

Shares of Novo Nordisk A/S (NYSE: NVO) declined from $81.44 per share on June 13, 2025 to as low as $45.05 per share on August 06, 2025.

The plaintiff claims that between May 7, 2025 and July 28, 2025, the defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo Nordisk's growth potential, that notably, Novo Nordisk's asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives, and that the defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate said markets to achieve continued growth.

Those who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.